CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 164 enrolled
Drug / intervention
cilostazol +1 moredrug
Likely dose
cilostazol 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00822172
NCT00822172Phase 4Completed

Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication

Colorado Prevention Center·interventional·Posted Jan 14, 2009·Updated Nov 29, 2019

In Brief

A Phase 4 clinical trial evaluating Levocarnitine tartrate and cilostazol for Peripheral Vascular Disease and 2 related conditions. Completed, enrolled 164 participants across 24 sites.

Detailed Summary

The purpose of this study is to see how safe and effective L carnitine taken with cilostazol is compared to placebo taken with cilostazol for people with intermittent claudication. A second purpose of the study is to see if L-carnitine is absorbed into the blood stream.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2009
Enrollment StartSep 1, 2008
Primary CompletionNov 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.5 years ago

Interventions

Levocarnitine tartratedietary

Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.

cilostazoldrug

Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks. Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.